Standard BioTools Inc. (NASDAQ:LAB) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its position in Standard BioTools Inc. (NASDAQ:LAB) by 22.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 258,897 shares of the company’s stock after selling 73,484 shares during the period. Dimensional Fund Advisors LP owned about 0.07% of Standard BioTools worth $453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in LAB. Takeda Pharmaceutical Co. Ltd. acquired a new position in Standard BioTools during the fourth quarter worth $29,000. Cibc World Markets Corp acquired a new stake in shares of Standard BioTools in the fourth quarter valued at about $48,000. Simon Quick Advisors LLC acquired a new stake in shares of Standard BioTools in the fourth quarter valued at about $54,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Standard BioTools in the fourth quarter valued at about $70,000. Finally, HighTower Advisors LLC raised its position in shares of Standard BioTools by 13.0% in the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock valued at $162,000 after buying an additional 10,690 shares during the last quarter. 53.74% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of the company’s stock in a transaction on Friday, February 28th. The shares were bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the purchase, the director now owns 58,846,780 shares of the company’s stock, valued at $62,377,586.80. This represents a 8.92% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 23.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, KeyCorp cut shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

Standard BioTools Stock Performance

NASDAQ LAB opened at $1.08 on Friday. The firm has a 50 day simple moving average of $1.14 and a 200-day simple moving average of $1.49. Standard BioTools Inc. has a one year low of $0.95 and a one year high of $2.74. The firm has a market cap of $410.21 million, a price-to-earnings ratio of -1.52 and a beta of 1.80.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.